Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina

AIDS

Volumn 21, Issue 10, 2007, Pages 1355-1360

  Dilernia, Dario A ^a   Lourtau, Leonardo ^b   Gomez, Alejandro M ^a   Ebenrstejin, Juan ^b   Toibaro, Javier J ^b   Bautista, Christian T ^c,e   Marone, Rubén ^d   Carobene, Mauricio ^a   Pampuro, Sandra ^a   Gomez Carrillo, Manuel ^a   Losso, Marcelo H ^b   Salomón, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL RAMOS MEJÍA   (Argentina)

^c ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^d Nexo Non Governmental Gay Men Organization   (Argentina)

^e WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antiretroviral access; Developing countries; HIV drug resistance; Standards for quality HIV care; Surveillance

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARGENTINA; ARTICLE; BLOOD SAMPLING; BOOTSTRAPPING; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; COUNSELING; DENATURATION; DEVELOPING COUNTRY; ENZYME IMMUNOASSAY; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR PHYLOGENY; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; STRUCTURAL GENE; UNINDEXED SEQUENCE; VIRUS DIAGNOSIS; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

ADULT; ANTI-RETROVIRAL AGENTS; ARGENTINA; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; POPULATION SURVEILLANCE; REVERSE TRANSCRIPTASE INHIBITORS; RISK ASSESSMENT; URBAN HEALTH;

EID: 34249991418     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280b07db1     Document Type: Article

References (28)

1. Pillay D, Bhaskaran K, Jurriaans S, Prins M, Masquelier B, Dabis F, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
2. Weinstock HS, Zaidi I, Heneine W, Bennett D, Garcia-Lerma JG, Douglas JM, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 2004; 189:2174-2180.
3. Wensing AM, van de Vijver DA, Angarano G, Asjo B, Balotta C, Boeri E, et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 2005; 192:958-966.
4. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
5. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41:1316-1323.
6. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-848.
7. Bartlett JG, Lane HC, and the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Washington DC: US Department of Health & Human Services; 2006.
8. World Health Organization. Progress on Global Access to HIV Antiretroviral Therapy - An Update on '3 by 5′. Geneva: World Health Organization; 2005.
9. Petersen ML, Boily MC, Bastos FI. Assessing HIV resistance in developing countries: Brazil as a case study. Rev Panam Salud Publica 2006; 19:146-156.
10. Soares MA, Brindeiro RM, Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS 2004; 18 (suppl 3):S9-S13.
11. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-limited Settings: Treatment Guidelines for a Public Health Approach. Geneva: World Health Organization; 2003.
12. Kijak GH, Pampuro SE, Avila MM, Zala C, Cahn P, Wainberg MA, Salomon H. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 2001; 6:71-77.
13. Petroni A, Deluchi G, Pryluka D, Rotryng F, Bortolozzi R, Lopardo G, et al. Update on primary HIV-1 resistance in Argentina: Emergence of mutations conferring high-level resistance to non-nucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006; 42:506-510.
14. World Health Organization. Guidelines for Surveillance of HIV Drug Resistance. Geneva: World Health Organization; 2003.
15. Janssen RS, Satten GA, Stramer SL, Rawal BD, O'Brien TR, Weiblen BJ, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280:42-48.
16. Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, Mei JV. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr 2003; 33:625-634.
17. Korber B, Foley BT, Kuiken C, Pillai SK, Sodroski JG. Numbering Positions in HIV Relative to HXB2CG. Los Alamos, New Mexico: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 1998.
18. Gomez-Carrillo M, Quarleri JF, Rubio AE, Carobene MG, Dilernia D, Carr JK, Salomon H. Drug resistance testing provides evidence of the globalization of HIV type 1: a new circulating recombinant form. AIDS Res Hum Retroviruses 2004; 20:885-888.
19. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med 2005; 13:51-57.
20. Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41:95-98.
21. Kumar S, Tamura K, Nei M. MEGA3: Integrated software for Molecular Evolutionary Genetics Analysis and sequence alignment. Brief Bioinform 2004; 5:150-163.
22. Lole KS, Bollinger RC, Paranjape RS, Gadkari D, Kulkarni SS, Novak NG, et al. Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160.
23. Hamilton G, Péné MD, Fenoy D, Aayma A, Kuperman G, Giraldez ML, et al. Situación de los infectados con VIH en la Argentina. Boletín sobre VIH/SIDA en la Argentina 2005; 10:20-26.
24. Center for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic. Morbidity and Mortality Weekly Report 2003; 52:329-332.
25. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-1761.
26. Cane P, Chrystie I, Dunn D, Evans B, Geretti AM, Green H, et al. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 2005; 331:1368.
27. de Mendoza C, Rodriguez C, Colomina J, Tuset C, Garcia F, Eiros JM, et al. Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. Clin Infect Dis 2005; 41:1350-1354.
28. Bennett D, Rhee SY, Pillay D, Mille, V, Snadstrom P, Schapiro J, et al. HIV-1 protease and reverse transcriptase mutations for HIV drug resistance epidemiology and surveillance. 13th Conference on Retrovirus and Opportunistics Infections. Denver, Colorado, USA. 2006.